Art

J-GLOBAL ID：201902216289219295   Reference number：19S1356409

Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status

Author (8)： Kato, Junko (Department of Surgical Oncology, Graduate School of Medicine, Gifu University) ,  Kanematsu, Masako (Department of Surgical Oncology, Graduate School of Medicine, Gifu University) ,  Gaowa, Siqin (Department of Surgical Oncology, Graduate School of Medicine, Gifu University) ,  Mori, Ryutaro (Department of Surgical Oncology, Graduate School of Medicine, Gifu University) ,  Tanahashi, Toshiyuki (Department of Surgical Oncology, Graduate School of Medicine, Gifu University) ,  Matsuhashi, Nobuhisa (Department of Surgical Oncology, Graduate School of Medicine, Gifu University) ,  Yoshida, Kazuhiro (Department of Surgical Oncology, Graduate School of Medicine, Gifu University) ,  Futamura, Manabu (Department of Breast and Molecular Oncology, Graduate School of Medicine, Gifu University)
Material： International Journal of Cancer
Volume： 138  Issue： 6  Page： 1516-1527  Publication year： 2016 
JST Material Number： SCOPUS  ISSN： 0020-7136  CODEN： IJCNA 
Country of issue： United States (USA)  Language： English (EN)

Terms in the title (3)： Cetuximab ,  Cancer ,  KRAS